Addex Therapeutics Ltd Cash Flow Conversion Efficiency
Addex Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has a cash flow conversion efficiency ratio of -0.233x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-765.84K) by net assets ($3.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Addex Therapeutics Ltd (2006–2025)
Cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. This chart illustrates how Addex Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ADXN stock price for real-time trading data and today's change.
Addex Therapeutics Ltd Cash Flow Conversion Ratio Explained
Addex Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Addex Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Addex Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see market cap of Addex Therapeutics Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Techfast Holdings Bhd
KLSE:0084
|
0.129x |
|
American Rebel Holdings Inc
NASDAQ:AREB
|
-0.514x |
|
H3 Energy Limited
AU:H3E
|
0.355x |
|
Cash.Medien AG
HM:MF8
|
N/A |
|
CCSC Technology International Holdings Limited Ordinary Shares
NASDAQ:CCTG
|
-0.042x |
|
E-Home Household Service Holdings Ltd
NASDAQ:EJH
|
0.004x |
|
Indo Pureco Pratama Tbk PT
JK:IPPE
|
0.000x |
|
Stellar AfricaGold Inc.
V:SPX
|
-0.152x |
Annual Cash Flow Conversion Efficiency for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Addex Therapeutics Ltd from 2006 to 2025. Review Addex Therapeutics Ltd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.77 Million | $-2.08 Million | -0.435x | +21.58% |
| 2024-12-31 | $9.68 Million | $-5.37 Million | -0.555x | +92.04% |
| 2023-12-31 | $1.15 Million | $-7.99 Million | -6.977x | -108.55% |
| 2022-12-31 | $4.91 Million | $-16.44 Million | -3.346x | -285.22% |
| 2021-12-31 | $16.93 Million | $-14.71 Million | -0.869x | -4.18% |
| 2020-12-31 | $14.61 Million | $-12.18 Million | -0.834x | -124.41% |
| 2019-12-31 | $25.52 Million | $-9.48 Million | -0.372x | -932.20% |
| 2018-12-31 | $39.24 Million | $1.75 Million | 0.045x | +102.81% |
| 2017-12-31 | $1.34 Million | $-2.13 Million | -1.590x | +87.10% |
| 2016-12-31 | $218.59K | $-2.69 Million | -12.326x | -680.44% |
| 2015-12-31 | $1.66 Million | $-2.63 Million | -1.579x | -105.86% |
| 2014-12-31 | $2.35 Million | $-1.80 Million | -0.767x | +85.28% |
| 2013-12-31 | $3.03 Million | $-15.78 Million | -5.214x | -188.38% |
| 2012-12-31 | $16.29 Million | $-29.45 Million | -1.808x | -130.40% |
| 2011-12-31 | $33.84 Million | $-26.55 Million | -0.785x | -61.27% |
| 2010-12-31 | $64.41 Million | $-31.34 Million | -0.487x | +4.14% |
| 2009-12-31 | $77.58 Million | $-39.38 Million | -0.508x | -239.45% |
| 2008-12-31 | $118.99 Million | $-17.79 Million | -0.150x | +36.53% |
| 2007-12-31 | $140.11 Million | $-33.00 Million | -0.236x | +49.08% |
| 2006-12-31 | $42.28 Million | $-19.56 Million | -0.463x | -- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more